CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

The approval is based on data from a comprehensive late-stage program, which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta ...

Trikafta—known as Kaftrio in Europe—itself has contributed $7.5 billion during the first nine months of 2024. But investors’ attention has lately shifted to suzetrigine, a nonaddictive pain ...

The FDA on Fri­day is­sued two si­mul­ta­ne­ous cys­tic fi­bro­sis ap­provals for Ver­tex Phar­ma­ceu­ti­cals but in­clud­ed high-lev­el safe­ty warn­ings for both.

which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta (Kaftrio in Europe), which is required to be administered twice daily.

Separately, the FDA expanded the indication for Vertex's Trikafta on Friday to include cystic fibrosis patients with additional genetic variants. The FDA initially approved Trikafta in 2019 for ...

TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR) ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...